120 related articles for article (PubMed ID: 10605307)
1. Economic and organizational aspects in the management of prostate cancer.
Cellini N; Luzi S; Morganti AG; Mattiucci GC; Smaniotto D; Racioppi M
Rays; 1999; 24(3):460-71. PubMed ID: 10605307
[TBL] [Abstract][Full Text] [Related]
2. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
Urology; 1995 Sep; 46(3):277-89. PubMed ID: 7544931
[No Abstract] [Full Text] [Related]
3. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
[TBL] [Abstract][Full Text] [Related]
4. Rising prostate specific antigen after radical prostatectomy: a case based review.
Nasr R; Goldenberg SL
Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
[TBL] [Abstract][Full Text] [Related]
5. [Prostate cancer: medicoeconomic aspects].
Kanso C; Etner J; Debré B; Zerbib M
Prog Urol; 2010 Feb; 20(2):85-90. PubMed ID: 20142048
[TBL] [Abstract][Full Text] [Related]
6. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
8. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
Adolfsson J
Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
[TBL] [Abstract][Full Text] [Related]
10. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
[TBL] [Abstract][Full Text] [Related]
14. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer in Victoria in 1993: patterns of reported management.
Frydenberg M; Giles GG; Mameghan H; Thursfield VJ; Millar J; Wheelahan JB; Bolton DM; Syme RR
Med J Aust; 2000 Mar; 172(6):270-4. PubMed ID: 10860092
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
18. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
Postma R; Roobol M; Schröder FH; van der Kwast TH
Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of prostate cancer screening with prostate-specific antigen.
Imamura T; Yasunaga H
Int J Urol; 2008 Apr; 15(4):285-8. PubMed ID: 18380812
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen recurrence after definitive therapy.
Freedland SJ; Moul JW
J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
